ENOV
Enovis Corporation
ENOV
Enovis Corporation
Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality devic
Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Perform
Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript
Online lender Enova International saw improvements in both originations and credit during the second quarter, with consumer spending remaining resilient and small businesses optimism increasing, Enova
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and liv